GLP1R and obesity disorder: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), such as semaglutide and liraglutide, and the dual gastric inhibitory polypeptide (GIP) and GLP‐1 RA, tirzepatide, are drugs authorised in the UK by NICE (National Institute for Health and Care Excellence) for the management of obesity and/or type 2 diabetes mellitus (T2DM) [3, 4, 5].